| Literature DB >> 33134130 |
Oladotun A Olayode1, Michael Oluwatoyin Daniyan1, Gbola Olayiwola2.
Abstract
BACKGROUND AND AIM: The many pharmacological potentials of Stachytarpheta cayennensis (L.C. Rich) Vahl, especially in managing central nervous system disorders, hypertension, diabetes and infections, have made it a subject of abuse, necessitating the need to ascertain its safety. This study therefore investigated the toxic effects of the leaf extract of S. cayennensis in rats following acute and 28-day repeated doses in male and female rats. EXPERIMENTAL PROCEDURE: Acute and repeated dose studies were conducted in male and female groups of rats (135-150 g), using OECD 423 and 407 Tests guidelines respectively. Functional observational battery, and body weights were monitored. Blood samples were analysed for haematological and plasma biochemical indices. Organs (brain, kidneys and liver) specimen were collected and weighed. Kidney and liver specimen were subjected to histopathological analysis. RESULTS ANDEntities:
Keywords: Acute toxicity; Organotoxicity; Repeated dose toxicity; Safety assessment; Stachytarpheta cayennesis
Year: 2019 PMID: 33134130 PMCID: PMC7588336 DOI: 10.1016/j.jtcme.2019.05.001
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Fig. 1Schematic representation of the experimental procedures. Experiments were performed separately in male and female rats.
Fig. 2Average relative change in body weights following single and repeated dose administration of the extract of Data were expressed as mean ± SEM, n = 5, p < 0.05. *Compare with respective controls (male or female). a Compare effect on female with male for each dose level. b Compare with respective Toxicity set. All statistical analysis were done using Student's T Test for pairwise comparison.
Organ - body weights and organ-brain weight ratio following single and repeated doses of the extract.
| Treatment Group | Organ - Body weights ratio | Organ - Brain weights ratio | |||||
|---|---|---|---|---|---|---|---|
| Liver | Kidney | Brain | Liver | Kidney | |||
| Acute Toxicity | Control | 3.20 ± 0.15 | 0.73 ± 0.06 | 1.37 ± 0.06 | 2.36 ± 0.12 | 0.53 ± 0.03 | |
| 3.78 ± 0.13 | 0.77 ± 0.04 | 1.25 ± 0.13 | 3.04 ± 0.12 | 0.62 ± 0.02 | |||
| 1250 mg/kg | 3.56 ± 0.09 | 0.72 ± 0.03 | 1.30 ± 0.06 | 2.76 ± 0.14 | 0.56 ± 0.01 | ||
| 4.03 ± 0.09 | 0.82 ± 0.04 | 1.25 ± 0.07 | 3.29 ± 0.20 | 0.67 ± 0.02 | |||
| 2500 mg/kg | 3.20 ± 0.08 | 0.62 ± 0.02 | 1.21 ± 0.04 | 2.65 ± 0.07 | 0.51 ± 0.02 | ||
| 3.88 ± 0.10 | 0.74 ± 0.04 | 1.28 ± 0.08 | 3.09 ± 0.23 | 0.58 ± 0.03 | |||
| 5000 mg/kg | 3.60 ± 0.07* | 0.77 ± 0.03 | 1.37 ± 0.04 | 2.65 ± 0.11 | 0.57 ± 0.03 | ||
| 3.72 ± 0.17 | 0.63 ± 0.04* | 1.20 ± 0.03 | 3.12 ± 0.19 | 0.60 ± 0.00 | |||
| Repeated Dose TS | Control | 4.07 ± 0.30 | 0.65 ± 0.04 | 0.96 ± 0.03 | 4.33 ± 0.24 | 0.70 ± 0.06 | |
| 4.95 ± 0.15 | 0.85 ± 0.33 | 1.05 ± 0.02 | 4.35 ± 0.41 | 0.75 ± 0.02 | |||
| 250 mg/kg | 4.17 ± 0.15 | 0.74 ± 0.04 | 0.96 ± 0.02 | 4.34 ± 0.18 | 1.77 ± 0.74 | ||
| 3.79 ± 0.25* | 0.77 ± 0.04 | 1.12 ± 0.06 | 3.48 ± 0.21 | 0.70 ± 0.03 | |||
| 500 mg/kg | 3.71 ± 0.06 | 0.59 ± 0.07 | 0.88 ± 0.04 | 4.26 ± 0.24 | 0.79 ± 0.05 | ||
| 3.76 ± 0.23* | 0.72 ± 0.04 | 1.03 ± 0.05 | 3.71 ± 0.20 | 0.71 ± 0.04 | |||
| 1000 mg/kg | 4.09 ± 0.18 | 0.80 ± 0.07 | 1.08 ± 0.04 | 3.80 ± 0.28 | 0.75 ± 0.06 | ||
| 4.21 ± 0.25* | 0.69 ± 0.04 | 0.98 ± 0.06 | 4.44 ± 0.32 | 0.72 ± 0.04 | |||
| Repeated Dose RS | Control | 4.22 ± 0.13 | 0.72 ± 0.03 | 1.09 ± 0.07 | 3.93 ± 0.19 | 0.69 ± 0.08 | |
| 4.48 ± 0.30 | 0.74 ± 0.03 | 1.02 ± 0.03 | 4.38 ± 0.06 | 0.72 ± 0.02 | |||
| 250 mg/kg | 4.40 ± 0.19 | 0.73 ± 0.04 | 0.95 ± 0.03 | 4.70 ± 0.33 | 0.78.±0.05 | ||
| 3.89 ± 0.14 | 0.69 ± 0.03 | 0.94 ± 0.05 | 4.16 ± 0.21 | 0.74 ± 0.03 | |||
| 500 mg/kg | 4.26 ± 0.12 | 0.66 ± 0.03 | 0.95 ± 0.03 | 4.56 ± 0.23 | 0.70 ± 0.01 | ||
| 3.97 ± 0.22 | 0.71 ± 0.02 | 0.97 ± 0.07 | 4.16 ± 0.20 | 0.74 ± 0.04 | |||
| 1000 mg/kg | 3.93 ± 0.12 | 0.63 ± 0.33 | 0.95 ± 0.03 | 4.14 ± 0.05 | 0.66 ± 0.03 | ||
| 4.16 ± 0.30 | 0.70 ± 0.04 | 0.92 ± 0.02* | 4.55 ± 0.36 | 0.76 ± 0.06 | |||
Data were expressed as mean ± SEM, n = 5, and p < 0.05, TS = Toxicity Set, RS = Recovery set.
*Compare with respective controls (male or female) was done using ANOVA followed by Dunnett's post hoc test; while.
Compare effect on female with male for each dose level and.
Compare with respective Toxicity set were done using Student's T-test. All statistics were done using Graph Pad Prism version 5.01 (Graph Pad software, San Diego, California, U.S.A).
Hematological parameters following single and 28 days repeated dose oral administration of the extract of S. Cayennensis.
| Treatment Groups | WBC (x109/L) | Platelet (x109/L) | RBC (x1012/L) | Haematocrit (%) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | Male | Female | ||
| Acute Toxicity | Control | 5.00 ± 0.39 | 5.04 ± 0.60 | 502.60 ± 50.37 | 686.40 ± 23.61a | 7.38 ± 0.31 | 8.30 ± 0.14a | 56.96 ± 1.41 | 57.30 ± 0.60 |
| 1250 mg/kg | 5.00 ± 0.59 | 4.50 ± 0.23 | 430.00 ± 38.17 | 644.80 ± 38.64a | 7.22 ± 0.19 | 7.17 ± 0.44* | 56.32 ± 1.73 | 48.40 ± 1.33*a | |
| 2500 mg/kg | 5.00 ± 0.88 | 6.40 ± 1.08 | 490.60 ± 42.00 | 641.20 ± 45.93a | 6.86 ± 0.70 | 7.70 ± 8.20 | 46.80 ± 2.72* | 54.50 ± 1.22a | |
| 5000 mg/kg | 4.60 ± 0.80 | 5.52 ± 0.36 | 672.40 ± 35.83* | 642.80 ± 44.56 | 7.86 ± 0.06 | 7.19 ± 0.84 | 48.10 ± 2.43* | 57.50 ± 0.64a | |
| Repeated Dose TS | Control | 4.90 ± 0.47 | 5.60 ± 0.71 | 408.80 ± 43.00 | 479.20 ± 44.73 | 6.90 ± 0.85 | 6.99 ± 0.12 | 40.50 ± 1.53 | 44.72 ± 1.92 |
| 250 mg/kg | 4.90 ± 0.69 | 3.56 ± 0.52* | 609.40 ± 48.92* | 652.40 ± 25.00* | 7.10 ± 0.46 | 7.60 ± 0.25 | 52.50 ± 1.11* | 51.12 ± 1.58* | |
| 500 mg/kg | 5.10 ± 0.53 | 3.68 ± 0.74 | 657.60 ± 47.73* | 677.20 ± 15.01* | 6.70 ± 0.80 | 7.45 ± 0.21 | 45.30 ± 2.47 | 53.68 ± 2.17*a | |
| 1000 mg/kg | 4.30 ± 0.78 | 6.40 ± 1.01 | 655.40 ± 41.99* | 706.40 ± 35.56* | 7.68 ± 0.41 | 7.11 ± 0.26 | 49.60 ± 2.01* | 48.80 ± 1.89 | |
| Repeated Dose RS | Control | 5.60 ± 3.73 | 5.20 ± 0.59 | 569.60 ± 41.77b | 711.20 ± 50.45b | 6.80 ± 0.84 | 6.45 ± 0.70 | 49.80 ± 1.25b | 44.60 ± 2.40 |
| 250 mg/kg | 3.60 ± 0.65 | 4.40 ± 0.57 | 323.20 ± 43.00*b | 611.80 ± 40.53a | 7.90 ± 0.12 | 5.93 ± 0.81a | 56.70 ± 1.19* | 44.50 ± 2.69a | |
| 500 mg/kg | 3.40 ± 0.77 | 5.10 ± 0.69 | 314.80 ± 49.93* | 587.80 ± 46.75a | 6.22 ± 0.86 | 6.45 ± 0.74 | 44.30 ± 1.11* | 46.00 ± 2.75 | |
| 1000 mg/kg | 3.82 ± 0.79 | 5.30 ± 0.68 | 269.00 ± 27.4*b | 613.60 ± 43.00a | 5.35 ± 0.43b | 5.60 ± 0.63 | 41.80 ± 1.13*b | 42.40 ± 1.99b | |
Data were expressed as mean ± SEM, n = 5, and p < 0.05, TS = Toxicity Set, RS = Recovery set.
*compare with respective controls (male or female) was done using ANOVA followed by Dunnett's post hoc test; while.
a compare effect on female with male for each dose level and b compare with respective Toxicity set were done using Student's T-test. All statistics were done using Graph Pad Prism version 5.01 (Graph Pad software, San Diego, California, U.S.A).
Hematological parameters following single and 28 days repeated dose oral administration of the extract of S. Cayennensis.
| Treatment Groups | Haemoglobin (g/dl) | MCV (fl) | MCH (pg) | MCHC (g/dl) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | Male | Female | ||
| Acute Toxicity | Control | 13.70 ± 0.42 | 14.80 ± 0.25 | 77.18 ± 1.72 | 69.04 ± 0.74 | 18.56 ± 0.73 | 17.83 ± 0.39 | 24.05 ± 1.83 | 25.83 ± 0.85 |
| 1250 mg/kg | 13.50 ± 0.58 | 12.94 ± 0.87 | 78.01 ± 1.92 | 67.5 ± 1.77 | 18.7 ± 0.77 | 18.05 ± 1.31 | 23.97 ± 2.31 | 26.74 ± 2.2 | |
| 2500 mg/kg | 12.60 ± 1.02 | 13.70 ± 0.37* | 68.22 ± 3.42* | 70.78 ± 1.42 | 18.37 ± 1.72 | 17.79 ± 8.57 | 26.92 ± 3.74 | 25.14 ± 1.59 | |
| 5000 mg/kg | 13.70 ± 0.19 | 14.60 ± 0.21 | 61.20 ± 2.49* | 79.97 ± 1.48 | 17.43 ± 0.25 | 20.31 ± 1.05 | 28.48 ± 2.62 | 25.39 ± 0.85 | |
| Toxicity Set | Control | 13.10 ± 0.68 | 13.44 ± 0.20 | 58.70 ± 2.38 | 63.98 ± 2.04 | 18.99 ± 1.53 | 19.23 ± 0.32 | 32.35 ± 2.21 | 30.05 ± 2.12 |
| 250 mg/kg | 14.20 ± 0.08 | 19.70 ± 4.55 | 73.94 ± 1.57* | 67.26 ± 1.83 | 20.00 ± 0.54 | 25.92 ± 4.8 | 27.05 ± 1.19 | 38.54 ± 6.13 | |
| 500 mg/kg | 13.20 ± 0.47 | 14.48 ± 0.39* | 67.61 ± 3.27 | 72.05 ± 2.38* | 19.70 ± 1.27 | 19.44 ± 0.6 | 29.14 ± 2.94 | 26.97 ± 2.56 | |
| 1000 mg/kg | 14.30 ± 0.55 | 14.20 ± 0.46 | 64.58 ± 2.42 | 78.64 ± 2.15* | 18.62 ± 0.96 | 19.97 ± 0.72 | 28.83 ± 2.56 | 29.1 ± 2.35 | |
| Recovery Set | Control | 11.48 ± 1.10 | 13.30 ± 0.45 | 73.24 ± 2.09 | 69.15 ± 3.1 | 16.88 ± 1.94 | 20.62 ± 1.15 | 38.52 ± 2.35 | 29.82 ± 2.85 |
| 250 mg/kg | 11.90 ± 1.69 | 13.80 ± 0.60 | 71.77 ± 1.31 | 75.04 ± 3.5 | 15.06 ± 1.81 | 23.27 ± 1.41 | 32.43 ± 2.88 | 31.01 ± 3.29 | |
| 500 mg/kg | 10.40 ± 1.49 | 13.30 ± 0.41 | 71.22 ± 1.97 | 71.32 ± 3.49 | 16.72 ± 2.35 | 20.62 ± 1.15 | 42.8 ± 2.6 | 28.91 ± 3.16 | |
| 1000 mg/kg | 10.88 ± 1.54 | 13.40 ± 0.29 | 78.13 ± 1.56 | 75.71 ± 2.62 | 20.34 ± 1.97 | 23.93 ± 0.92 | 49.91 ± 2.67*, | 31.6 ± 2.28 | |
Data were expressed as mean ± SEM, n = 5, and p < 0.05, TS = Toxicity Set, RS = Recovery set.
*Compare with respective controls (male or female) was done using ANOVA followed by Dunnett's post hoc test; while.
Compare effect on female with male for each dose level and.
Compare with respective Toxicity set were done using Student's T-test. All statistics were done using Graph Pad Prism version 5.01 (Graph Pad software, San Diego, California, U.S.A).
Change in Plasma Biochemical indices following single and 28 days repeated dose administration of the extract of S. Cayennensis.
| Treatment Groups | AST (Ul) | ALT (Ul) | Urea (mmol/l) | Creatinine (mg/dl) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | Male | Female | ||
| Acute Toxicity | Control | 257.71 ± 3.82 | 233.58 ± 3.60 | 72.28 ± 4.19 | 86.27 ± 1.84 | 7.99 ± 0.46 | 8.77 ± 0.32 | 3.780 ± 0.17 | 3.98 ± 0.17 |
| 1250 mg/kg | 284.14 ± 0.79* | 393.33 ± 1.30*a | 75.98 ± 4.42 | 156.25 ± 4.38*a | 7.21 ± 0.74 | 8.60 ± 0.55 | 4.37 ± 0.09 | 5.84 ± 0.34*a | |
| 2500 mg/kg | 281.79 ± 3.75* | 304.70 ± 2.28*a | 55.36 ± 1.21* | 88.60 ± 3.20a | 7.80 ± 0.29 | 7.94 ± 0.70 | 5.97 ± 0.13* | 5.07 ± 0.21*a | |
| 5000 mg/kg | 334.60 ± 2.09* | 316.95 ± 2.62*a | 84.54 ± 1.76* | 95.91 ± 1.54*a | 9.25 ± 0.69* | 9.92 ± 0.31 | 6.83 ± 0.12* | 4.54 ± 0.53a | |
| Repeated Dose TS | Control | 231.19 ± 3.09 | 225.65 ± 3.24 | 79.47 ± 2.10 | 74.74 ± 2.86 | 7.72 ± 0.25 | 7.08 ± 0.38 | 3.31 ± 0.26 | 3.42 ± 0.29 |
| 250 mg/kg | 209.86 ± 2.52* | 168.91 ± 1.05*a | 67.13 ± 0.80* | 81.54 ± 3.30a | 8.24 ± 1.26 | 8.07 ± 0.24 | 7.34 ± 2.90* | 3.30 ± 0.36a | |
| 500 mg/kg | 176.42 ± 3.27* | 158.35 ± 0.49*a | 77.14 ± 0.76 | 113.91 ± 2.29*a | 9.79 ± 0.40* | 8.11 ± 0.21a | 5.57 ± 0.12* | 4.62 ± 0.25a | |
| 1000 mg/kg | 166.11 ± 2.58* | 129.23 ± 0.64*a | 90.48 ± 1.52* | 150.04 ± 2.85*a | 13.26 ± 1.89* | 8.75 ± 0.20*a | 5.66 ± 0.31* | 4.22 ± 0.17a | |
| Repeated Dose RS | Control | 245.75 ± 4.17 | 236.4 ± 3.48 | 75.96 ± 4.56 | 78.09 ± 3.58 | 7.92 ± 0.50 | 7.14 ± 0.40 | 3.08 ± 0.14 | 3.10 ± 0.20 |
| 250 mg/kg | 331.16 ± 7.47*b | 250.32 ± 4.45ab | 68.50 ± 1.32 | 101.19 ± 4.61*ab | 5.76 ± 0.30*b | 5.62 ± 0.25*b | 5.43 ± 0.14*b | 3.49 ± 0.44a | |
| 500 mg/kg | 307.09 ± 3.63*b | 280.98 ± 2.80*ab | 110.86 ± 2.40*b | 108.80 ± 2.70* | 6.42 ± 0.26b | 5.35 ± 0.10*ab | 3.94 ± 0.29b | 2.99 ± 0.38b | |
| 1000 mg/kg | 348.74 ± 2.85*b | 270.77 ± 2.17*ab | 115.9 ± 2.83*b | 123.23 ± 0.96*ab | 6.83 ± 0.24b | 5.13 ± 0.37*ab | 3.88 ± 0.27b | 3.14 ± 0.16b | |
Data were expressed as mean ± SEM, n = 5, and p < 0.05, TS = Toxicity Set, RS = Recovery set.
*compare with respective controls (male or female) was done using ANOVA followed by Dunnett's post hoc test; while.
a compare effect on female with male for each dose level and b compare with respective Toxicity set were done using Student's T-test. All statistics were done using Graph Pad Prism version 5.01 (Graph Pad software, San Diego, California, U.S.A).
Fig. 3Histopathology of male and female rat kidney following single and repeated dose administration of the extract of . DCT, distal convoluted tubule; PCT, proximal convoluted tubule; G, glomerulus. Red arrows were used to identify pathological changes including presence of renal lesions/tissue haemorrhages. Staining was done using H&E and magnification was ×400.
Fig. 5Histopathology of male and female rat Kidneys and livers following 21 days of recovery after repeated dose administration of methanol extract of DCT, distal convoluted tubule; PCT, proximal convoluted tubule; G, glomerulus; H, hepatocyte; V, central vein; D, bile duct. Staining was done using H&E and magnification was ×400.
Fig. 4Histopathology of male and female rat livers following single and repeated dose administration of methanol extract of H, hepatocyte; V, central vein; D, bile duct. Red arrows were used to identify pathological changes including presence of hepatic lesions. Staining was done using H&E and magnification was ×400.